---
title: Living person sustained for >1 week with full replacement of all body below the neck (head and spinal cord preserved)
status: draft
dimensions: ["healthcare","labor","family"]
horizon: long
trigger: A living person communicates and acts in the world for a period of over 1 week, having none of their original body below the neck (excluding the spinal cord). Full replacement of limbs, body, and internal organs (heart, lungs, liver, kidneys, GI tract, endocrine, reproductive) — whether by xenografts, bioengineered organs, mechanical/artificial substitutes, or combinations thereof. The brain and spinal cord remain biological and original. The person is verifiably conscious, communicating (speech, BCI, or otherwise), and sustained as a unified physiological system for at least 7 consecutive days post-procedure.
timeline: {"p10":2055,"p50":2075,"p90":2110}
confidence: low
sub_gates: [{"slug":"total-artificial-heart-destination-therapy-approved","p50":2034,"why":"TAH approved as permanent destination therapy (not bridge-to-transplant). Current state May 2026: BiVACOR titanium TAH (5 patients, 100-day record + ambulatory discharge) just earned FDA Breakthrough Device Designation; Carmat/Aeson reached 100 implants by Feb 2025 but parent went into French receivership July 2025 (now under Picard Medical/SynCardia parent reorg); SynCardia patient at 2,900 days (~8 years) continuous support — the longest-ever TAH survival. SynCardia destination-therapy IDE was filed years ago but pivotal trial still incomplete. P50 2034 reflects BiVACOR pivotal trial completing ~2030-2032 + FDA review."},{"slug":"pig-organ-xenotransplant-routine","p50":2038,"why":"Pig kidney/heart/liver/lung xenotransplants achieve routine 1-year+ survival rates competitive with allotransplantation. Current state: Tim Andrews 271 days with eGenesis pig kidney (record, Jan-Oct 2025); United Therapeutics EXPAND Phase I dosed first patient Nov 2025 (50 patients planned); eGenesis Phase I underway (33 patients planned); pig heart (Bennett 60d, Faucette 40d both died early); pig lung 9 days (brain-dead); pig liver auxiliary 171 days (Anhui Medical 2024). FDA cleared 3 IND applications Feb 2024-April 2025. Heart and lung xeno are 3-5 years behind kidney. P50 2038 = ~12 years for the slowest of the four (lung) to reach routine clinical use."},{"slug":"chronic-implantable-artificial-lung","p50":2045,"why":"Implantable artificial lung supporting a patient for months-to-years without ICU-grade external infrastructure. Current state May 2026: ECMO record 182 days bridge-to-transplant; Northwestern Jan 2026 case kept a patient alive 48 hours without any lungs using total artificial lung system (bridge to double lung transplant). All current artificial lungs are extracorporeal, ICU-bound, with massive infection/clotting risks. No durable implantable artificial lung exists. Lungs are the most demanding gas-exchange surface in the body; miniaturization to implantable scale while maintaining gas-exchange area is a multi-decade engineering challenge. P50 2045 assumes pig lung xeno (with porcine genetic edits + 10-year safety record) is the more likely path than fully synthetic."},{"slug":"bci-speech-restored-locked-in","p50":2031,"why":"BCI achieves >100 wpm speech decoding in a fully locked-in patient with FDA approval. Already approaching threshold: ALS-patient demonstration of 62 wpm BCI speech (3x prior record); Neuralink VOICE trial (NCT07256) underway with FDA Breakthrough Designation for speech restoration; Synchron COMMAND-12 patients with endovascular implants. Neuralink integrated Grok (May 2025) for signal-decoding ambiguity. Sub-gate is upstream — communication is largely a solved problem within 5-8 years, well before this gate's main demand."},{"slug":"head-transplant-cephalic-anastomosis-living-human","p50":2065,"why":"First successful living-donor whole-body transplantation (head/brain retained, full body replaced) — Canavero's HEAVEN protocol, BrainBridge concept, or successor. Current scientific consensus: spinal cord reconnection remains the binding constraint; PEG/GEMINI fusogen approach unproven at full transection in primates; Canavero's 2017 'corpse' demonstration was not a living transplant. Most surgical and bioethics experts say not before 2030 at earliest; majority think it will not happen this century in current form because spinal cord regeneration would obviate need for whole-body swap and BCI-controlled prostheses are converging faster than nerve fusion. P50 2065 if it happens at all; could be 2100+ or never."},{"slug":"integrated-multi-organ-replacement-platform","p50":2070,"why":"All major thoracic + abdominal organ functions replaced concurrently in a single patient as a unified life-support platform (TAH + artificial/xeno lung + artificial/xeno liver + artificial/xeno kidney + nutritional support + endocrine substitution) sustained >30 days. No medical center has ever attempted multi-organ artificial replacement; the closest is multi-organ transplant from cadaveric donors (heart + lung + kidney + liver from one donor cluster). The systems-integration problem is the gate's hardest unsolved engineering question — every artificial organ has its own anticoagulation, infection, immune, and control-loop requirements that don't compose cleanly. P50 2070 reflects the multi-decade gap between single-organ and integrated multi-organ artificial life support."}]
history: [{"date":"2026-05-31T00:00:00.000Z","p10":2055,"p50":2075,"p90":2110,"why":"Initial estimate from initial research."}]
cross_gate: [{"other":"human-aging-halted","relation":"substitutes","strength":"medium","note":"If aging is halted (P50 2048), the demand for full-body replacement drops dramatically — people don't need new bodies if the original keeps working. Conversely, full-body replacement is a brute-force longevity intervention that BYPASSES aging biology: if cellular reprogramming and senolytics keep failing in clinical trials, body-replacement becomes the only credible path to extreme longevity. Both gates target life-extension but via opposite mechanisms (preserve-biology vs replace-biology). Substitutive in the consumer demand sense; both gates passing would mean two parallel longevity stacks coexist (the rich do body-replacement; the masses do geroprotectors)."},{"other":"ai-agent-30pct-knowledge-work","relation":"enables","strength":"medium","note":"AI accelerates every component: drug discovery for immunosuppressants (Insilico-style), organ-on-chip simulation, CRISPR design for pig xenografts (eGenesis 69-gene-edit pigs are the AI-design ceiling today), surgical planning, control loops for closed-loop artificial organs, and BCI signal decoding (Neuralink+Grok). AI compresses biomedical R&D cycles 3-10x, pulling P10 forward but not transforming the fundamental biological constraints."},{"other":"humanoid-self-replication-factory","relation":"enables","strength":"weak","note":"Humanoid manufacturing infrastructure could mass-produce artificial organ components and surgical robotic systems at lower cost; bioreactor automation reduces cost-per-organ-equivalent. Indirect — humanoids do not directly build artificial hearts but they reduce the unit cost of all complex medical hardware by 1-2 orders of magnitude. Weak but directionally positive."},{"other":"humanoid-10m-households","relation":"substitutes","strength":"weak","note":"Humanoid eldercare in the home addresses the same fundamental demand (independence in advanced age/illness) at much lower cost and lower medical risk than body-replacement. If humanoid caregivers + spinal cord stimulators + exoskeletons restore agency to disabled and elderly humans, the demand pressure for body-replacement decreases. Substitutive on the use-case dimension."},{"other":"corporate-sovereignty-territory","relation":"correlates","strength":"weak","note":"Both gates require regulatory environments outside conventional national jurisdiction. Body-replacement is unlikely to be approved by FDA/EMA before 2050 due to bioethics constraints; corporate medical zones or charter-city hospitals (Honduras, Próspera-type) may host the first procedures. Weak correlation through shared 'jurisdiction-shopping' for cutting-edge medicine."},{"other":"global-economy-explosive-growth","relation":"enabled_by","strength":"medium","note":"Body-replacement at the integrated multi-organ scale is likely a $10-50M procedure even at maturity (today: each xenotransplant alone costs ~$1-2M with immunosuppression). Without explosive growth in global wealth (P50 2049), the pool of patients who can afford it remains too small to sustain the clinical research infrastructure. The two gates likely co-occur in the same wealth + tech wave."}]
key_dependencies: [{"factor":"Xenotransplant multi-organ durability milestone","kind":"capability","direction":"both","linked_gate":null,"impact":"Pig heart and lung xeno durability (currently ~60d and 9d) must reach 30+ days concurrently; failure to advance beyond current records delays P50 by 10-20 years."},{"factor":"Multi-organ integration systems engineering","kind":"capability","direction":"accelerates","linked_gate":null,"impact":"Demonstrating concurrent TAH + artificial lung + artificial liver + renal support in a single patient for 30+ days would pull P50 forward by an estimated decade; absence of any such attempt keeps P50 at 2075."},{"factor":"Human aging halted gate outcome","kind":"gate","direction":"both","linked_gate":"human-aging-halted","impact":"If aging is halted (P50 2048), consumer demand for body-replacement collapses to a trauma/ALS niche, shrinking R&D investment and potentially delaying gate by 20+ years; if aging-halt fails, body-replacement becomes the primary longevity path, accelerating investment."},{"factor":"FDA destination therapy approval for total artificial heart","kind":"regulation","direction":"accelerates","linked_gate":null,"impact":"FDA approval of TAH as permanent destination therapy (not bridge-to-transplant) unlocks the clinical and regulatory pathway for sustained multi-organ artificial support; expected ~2034 but delays cascade directly into P50."},{"factor":"Novel immunosuppression for multi-organ xenotransplant","kind":"capability","direction":"accelerates","linked_gate":null,"impact":"No clinical framework exists for combinatorial immunosuppression across 4+ simultaneous xenografts; a validated regimen would shift P50 forward by 5-10 years, while absence of one is a hard blocker."},{"factor":"Regulatory jurisdiction for first procedure","kind":"regulation","direction":"accelerates","linked_gate":"corporate-sovereignty-territory","impact":"FDA/EMA unlikely to approve before 2050+; availability of permissive medical jurisdiction (charter cities, Dubai free zones) could pull the first attempt forward by 10-15 years relative to OECD-only scenario."},{"factor":"AI-accelerated biomedical R&D cycles","kind":"gate","direction":"accelerates","linked_gate":"ai-agent-30pct-knowledge-work","impact":"AI compressing drug-discovery and CRISPR-design cycles 3-10x could pull P10 forward by ~5 years, particularly for immunosuppressant design and pig-xenograft gene-editing beyond eGenesis's current 69-gene-edit ceiling."}]
external_calibration: {"metaculus":"https://www.metaculus.com/questions/5211/first-human-head-transplant-when/","manifold":null,"expert_consensus":"Strong skepticism from mainstream medical community; modest optimism from transhumanist-adjacent researchers. Sergio Canavero (HEAVEN/GEMINI): claims feasibility by 2030, has consistently missed his predicted dates (originally 2017); was to operate on Spiridonov 2017 but patient withdrew. Hashem Al-Ghaili (BrainBridge concept video, May 2024): 8-year horizon to first attempt — explicitly a speculative concept piece, no real company. Bartley Griffith (UMD pig heart surgeon): xenotransplants will be routine within 5-10 years for single organs; multi-organ is decades away. Yale BrainEx team: pig brain perfusion (4 hours post-mortem) demonstrates the brain can survive isolated; living-human isolated-brain support is decades from clinical use. American Society of Transplant Surgeons: explicit body-transplantation is 'not within reasonable medical horizon'; the field is converging on organ-by-organ replacement, not whole-body. Mainstream bioethics consensus: spinal cord reconnection is the binding scientific constraint; if solved, the procedure becomes a transplant rather than a 'brain in a vat' scenario. Metaculus 'first human head transplant when': community date range broadly 2040-2100+ with no near-term clustering. Mind-uploading / brain-emulation (P50 ~2070-2100 across Metaculus questions) is the more likely 'consciousness transplant' path than physical body-replacement. Cryonics community (Alcor, Tomorrow Biostasis): preserves brain on the bet that future technology will reanimate — implicit consensus that the technology to revive into a new body is >50 years away. Aubrey de Grey (SENS): prefers cellular repair to body-replacement; views body-replacement as 'crude.' Note: this gate has the widest expert disagreement of any in the basket — ranging from 'feasible by 2030' (Canavero) to 'never' (mainstream transplant surgery)."}
last_updated: "2026-05-31T00:00:00.000Z"
sources_count: 38
---

## TL;DR

This gate asks when one living person will, for at least a week, exist as a biological brain (plus spinal cord) maintained inside an otherwise fully replaced body — every organ below the neck either an artificial machine, a xenograft, a bioengineered tissue, or some combination. **P50 2075, P10 2055, P90 2110.** The trigger is enormously more demanding than any single organ replacement: every component on the body-below-neck checklist (heart, lungs, liver, kidneys, GI tract, endocrine glands, reproductive organs, four limbs) must work simultaneously in one integrated patient for 7+ consecutive days, while the brain stays conscious and the person communicates and "acts in the world." As of May 2026, the longest a human has survived with even one xenotransplanted organ is **271 days** (Tim Andrews, eGenesis pig kidney) [3]; the longest with a total artificial heart is **2,900 days** (SynCardia patient) [11]; the longest with no native lungs is **48 hours** (Northwestern artificial lung bridge, Jan 2026) [6]. Pig hearts have managed only ~60 days in living recipients (Bennett 2022) and pig lungs only 9 days in a brain-dead recipient (Guangzhou Aug 2025) [4][7]. Multi-organ artificial replacement has never been attempted. The gate breaks into three layered problems: (1) **single-organ durability** — TAH destination therapy approval, pig-organ 1-year+ survival, durable implantable lung — likely solved 2034-2045; (2) **integrated multi-organ life support** — the systems-integration problem of running 6+ artificial/xeno organs concurrently with compatible anticoagulation, immunosuppression, control loops, and infection prevention — likely solved 2060-2080 if at all; and (3) **the cephalic anastomosis question** — whether the procedure requires a head transplant (which adds spinal cord reconnection, currently unsolved) or progressive in-situ organ replacement (which keeps the spinal cord and host vasculature). The trigger as written allows the second path, which is far more plausible. Optimist case (P10 2055): xenotransplant + artificial-organ stacks mature in parallel through the 2030s-2040s, an extreme-medicine clinical center attempts integrated multi-organ replacement in the early 2050s, and one patient holds together for >7 days. Pessimist case (P90 2110): the integration problem proves intractable, mind-uploading or aging-halt arrives first, and the use case never closes economically. The competing strategy of *halting biological aging* (P50 2048) is converging faster than body-replacement and likely makes this gate moot for most consumers; body-replacement persists as a niche extreme-medicine option for patients whose brain is healthy but whose body has failed catastrophically (e.g., severe burn, cancer cachexia, ALS late-stage).

## Current state (as of 2026-05-31)

**Total artificial heart — the most mature single-organ replacement.** The BiVACOR titanium TAH (magnetically-levitated single-rotor design) has implanted 5 patients in its FDA early feasibility study; the longest survivor was an Australian man at **100 days** with the device, including the first-ever ambulatory discharge from hospital (Feb-March 2025) [9][10]. FDA expanded the trial to 15 additional patients after the first 5 results. SynCardia (now under Picard Medical, IPO Aug 2025) has the only commercially-approved TAH (CardioWest, since ~2004 for bridge-to-transplant only); its longest-surviving patient reached **2,900 days** (~7.9 years) of continuous support [11]. Carmat's Aeson reached 100 implants by Feb 2025 but the parent company entered French receivership July 2025; the device is still implanted in select EU centers under MDR CE mark. No TAH has been approved as destination therapy (permanent implant) by FDA or EMA. LVADs (assist devices, not replacement) have records of 16 years on the same implanted device [11]. Carmat U.S. EFS second cohort approved April 2025; commercial launch in U.S. possibly from 2028 if it survives the receivership.

**Xenotransplantation — the most rapidly advancing organ replacement technology.** Tim Andrews (eGenesis 69-gene-edit pig kidney, MGH) survived **271 days** Jan-Oct 2025 — the all-time record for any animal-to-human transplant [3]. He received a human kidney match Jan 13 2026 ("first across the bridge"). Towana Looney (10-gene-edit pig kidney, NYU Langone, Nov 2024) reached **130 days** before rejection in April 2025 [16]. Rick Slayman (first living-human pig kidney, MGH March 2024) died after ~8 weeks of an arrhythmia unrelated to the kidney [1][17]. United Therapeutics' EXPAND Phase I (UKidney, 10-gene-edit, NYU Langone) dosed first patient Nov 3 2025; up to 50 patients planned [12]. eGenesis Phase I underway with up to 33 patients planned [3]. FDA granted 3 IND applications for xenotransplant trials Feb 2024-April 2025. Pig hearts have done much worse: David Bennett (Jan 2022) survived 60 days then died of heart failure (was found to have porcine cytomegalovirus); Lawrence Faucette (Sept 2023) survived 40 days [18]. World's first pig lung xenotransplant (Guangzhou Medical University, China, brain-dead 39-y/o recipient, Aug 2025) — organ functioned for **9 days** before substantial rejection [7]. World's first pig liver auxiliary xenotransplant (Anhui Medical, 2024) — auxiliary 10-gene-edit pig liver functioned **171 days** in a hepatocellular carcinoma patient [8]. The clinical trajectory: kidney is ~3 years ahead of liver, ~5 years ahead of heart, and ~6-8 years ahead of lung.

**Artificial lung — the weakest link.** Northwestern Medicine (Jan 29 2026) kept a 33-year-old patient alive for **48 hours with no biological lungs**, using a total artificial lung bridge to double lung transplant — the first documented case of any human existing without lungs [6]. ECMO record is **182 days** as bridge-to-transplant [13]. All current artificial lung devices are extracorporeal (ICU-only), require continuous anticoagulation, and have high infection/clotting rates. The bioartificial-lung field has been stuck since the 2010s; the gas-exchange-surface miniaturization problem is the fundamental constraint. Pig lung xenotransplant (9-day Guangzhou case) is the more credible long-term replacement path than fully synthetic.

**Artificial liver — bridging only.** MARS (Molecular Adsorbent Recirculating System) is FDA-approved for drug-induced acute liver failure and hepatic encephalopathy. ELAD (Extracorporeal Liver Assist Device) uses human/animal hepatocytes and reduced encephalopathy frequency vs. standard therapy (25% vs 58%). Both are bridging therapies measured in days, not months. Pig liver xenotransplant 171-day record (Anhui Medical, 2024, auxiliary not orthotopic) is the longest-duration solution available; orthotopic (complete replacement) has not been achieved beyond a few days [8].

**Artificial kidney — wearable advancing, implantable distant.** The wearable artificial kidney is a 5-kg belt connected via catheters; tolerated for 24 hours in trial with effective uremic solute clearance [14]. Implantable bioartificial kidney (silicon membrane + bioreactor of renal tubular cells) is in late-preclinical development. Current devices are 10-30 kg including dialysate. Pig kidney xenotransplant (eGenesis, UKidney) is the more credible near-term path. Conventional dialysis can sustain patients indefinitely (decades) but is not "below-the-neck replacement" in the gate's sense — it is extracorporeal.

**Prosthetic limbs and BCI control.** Neural-controlled robotic limbs (Open Bionics, DARPA Modular Prosthetic Limb, Mobius Bionics, Ottobock) are mature for upper-extremity replacement; sensory feedback is partial. UC Irvine/Caltech/USC bidirectional BCI exoskeleton (April 2026) showed brain-controlled walking with artificial leg sensation via direct sensory cortex stimulation [21]. Wandercraft Atalante X received second FDA indication expansion Nov 2025 (SCI C4-L5 + MS); Personal Exoskeleton self-balancing trial began Feb 2025 [22]. None of these are "limb replacement" per the gate's sense — they augment a paralyzed but otherwise intact limb. True limb amputation + prosthetic substitution is mature for arms and legs but the prosthetic is non-biological.

**BCI communication.** Neuralink: 12 participants, 15,000+ hours of device use as of late 2025; Noland Arbaugh (first patient, Jan 2025) uses BCI for video games and chess; ALS BCI patient hit **62 wpm speech decoding** (3x prior record) with >75% accuracy (Nature publication) [19][20]. Neuralink VOICE trial (NCT07256) for severe speech impairment underway with FDA Breakthrough Device Designation. Synchron COMMAND-12 patients with permanent endovascular Stentrode implants — no serious adverse events over 12 months [20]. Communication for brain-only patients is essentially solved at the 5-8 year horizon — the BCI bottleneck is no longer "can it work" but "scaling, FDA approval, manufacturing."

**Head transplant / cephalic anastomosis.** Robert White's 1970 monkey head transplant maintained consciousness for ~36 hours but the spine was severed and the head was paralyzed [23]. Sergio Canavero claimed in 2017 to have completed a "head transplant on a corpse" (not living); his 2016-2017 planned operation on Russian patient Valeriy Spiridonov was cancelled when Spiridonov got married and had a child [24]. BrainBridge (Hashem Al-Ghaili, May 2024) is a concept video by a science communicator, **not an actual incorporated company** — it claims an 8-year horizon but has no clinical infrastructure [25]. Spinal cord reconnection remains the binding scientific constraint; PEG/GEMINI fusogen approach (Canavero, Ren et al.) shows partial recovery in mice/rats/dogs but no successful complete-transection reconnection in primates. Vascular pedicle hemisected spinal cord transplantation (vSCT) tested in 8 paraplegic patients with PEG. Mainstream surgical opinion: not before 2030 at earliest, more likely never as currently conceived.

**Disembodied / isolated brain support.** Yale BrainEx (Sestan lab, 2019; replicated/extended 2022) restored cellular activity, oxygen/glucose consumption, and synaptic structure in pig brains 4 hours post-mortem, perfused for up to **36 hours**. Bexorg (commercial spinout, 2025) signed collaboration with Biohaven Ltd. (NYSE: BHVN) for CNS drug discovery using ex vivo perfused cadaver human and pig brains [26]. No isolated-brain-from-living-human research has been published or attempted (would be considered homicide under current law); the BrainEx-style protocols include anesthetics specifically to suppress consciousness and preempt the ethical question.

**Cryonics.** Alcor (Scottsdale, AZ) has 234 patients in cryopreservation, 1,444 living members; charges $80k for neuropreservation (head only), $220k whole-body. Tomorrow Biostasis (Berlin/Switzerland) has 1,500-5,500 worldwide sign-ups. No revival has ever been attempted; the field implicitly bets on >50-year horizon for body-reconstruction technology [27].

**Vertex VX-880 / zimislecel (Phase 1/2 results June 2025).** 10/12 patients (83%) became fully insulin-independent at 12 months on stem-cell-derived islet therapy; mean daily insulin dose reduction 92% [28]. Demonstrates feasibility of bioengineered endocrine-organ replacement, though requires lifelong immunosuppression and is single-organ (pancreas-islet only).

## Key uncertainties

1. **Does the trigger require head transplant or in-situ replacement?** The gate as written allows progressive replacement of organs in a patient who keeps their head and spinal cord — a far easier engineering path than cephalosomatic anastomosis. If interpreted strictly (no cephalic anastomosis needed), P50 is decades earlier. The phrasing "having none of their original body below the neck" implies all organs are replaced but is silent on whether the brain/head was ever detached. The most plausible path is progressive in-situ replacement.

2. **Spinal cord reconnection** (only relevant if head transplant is the path). No primate has ever recovered motor function after complete spinal cord transection. PEG fusogens show partial recovery in rodents/dogs but not at the cervical level needed for head transplant. If this problem requires solving, P50 slides to 2080+ or never.

3. **Multi-organ integration.** Every artificial/xeno organ has its own anticoagulation, infection-control, immunosuppression, and control-loop requirements that don't compose linearly. Running 6+ such systems concurrently in one patient is qualitatively different from running 1 — analogous to running 6 simultaneous solo organ transplants, which has never been attempted clinically.

4. **Xenotransplant durability.** Current pig kidney record is 271 days; pig heart ~60 days; pig lung 9 days. To sustain a "brain in a vat" for >1 week, all organs need to survive concurrently >1 week. Heart and lung xenografts are the binding constraint and may take 10-20 years to reach 30-day durability.

5. **Immunosuppression cocktails.** Multi-organ xenotransplants would require unprecedented immunosuppression regimens. Each organ may have different rejection profiles; combinatorial immunosuppression has not been clinically explored beyond dual-organ transplants (heart+lung, heart+kidney, etc.).

6. **Endocrine and metabolic replacement.** No artificial replacement exists for the adrenal glands, thyroid (beyond hormone supplementation), or the complex hormonal feedback loops involving the pancreas, kidneys, and gonads. Hormone-replacement-therapy can substitute for some functions but not the dynamic feedback control.

7. **GI tract and microbiome.** Total parenteral nutrition (TPN) can sustain a patient indefinitely without an intestine, but causes liver failure long-term and disrupts immune system development. Artificial intestine or pig intestine xenograft is barely studied.

8. **Brain perfusion stability.** Long-term brain support without endocrine input, with artificial blood composition, with non-pulsatile blood flow (from TAH centrifugal pumps), and with potential immunological cross-reactions is largely unstudied at the >30-day human scale.

9. **Bioethics and regulatory.** FDA/EMA are unlikely to approve a "brain in vat" procedure under any reasonable risk-benefit framework until each component is independently mature. The first attempts may happen in jurisdictions with looser oversight (China, charter cities, Dubai, Próspera-type SEZs). Public acceptance is unknown.

10. **Substitution by competing technologies.** Aging-halt (P50 2048) addresses the same end-user demand (avoiding death of an old body) without requiring replacement. Brain-emulation/mind-uploading (Metaculus P50 ~2070-2100) addresses it via a different mechanism (digital substrate). If either matures first, the demand for body-replacement collapses to a small niche.

## Sub-gate deep dives

### Total artificial heart approved as destination therapy (P50 2034)

The most mature artificial-organ replacement. BiVACOR's titanium TAH (5-patient EFS, 100-day record + first ambulatory discharge in March 2025) is the leading candidate for the first FDA destination-therapy approval. The FDA expanded the trial to 15 additional patients after the first 5 results and granted Breakthrough Device Designation [9][10]. Carmat/Aeson reached 100 implants but the parent went into French receivership July 2025; Picard Medical (parent of SynCardia and the Emperor TAH) IPO'd August 2025. The pivotal trial pathway for destination therapy typically requires 30-50 patients, 2-year follow-up — putting realistic FDA approval at 2032-2036. P50 2034 reflects BiVACOR's lead position assuming no major device failures.

### Pig organ xenotransplant routine (P50 2038)

Defined as: 1-year survival rates competitive with allotransplantation (~85-95% for kidney) for ANY pig organ in regular clinical use. Kidney is closest: eGenesis 271-day record [3], UKidney 50-patient Phase I, eGenesis 33-patient Phase I. Heart and liver are 3-5 years behind kidney; lung is 6-8 years behind. P50 2038 = ~12 years from first routine kidney xenotransplant approval (likely ~2028-2030) to all four organs at clinical maturity. The gate is unlikely to pass before xenotransplantation is routine — synthetic organs alone (TAH + artificial lung + dialysis) cannot replace the endocrine/metabolic functions of liver and pancreas.

### Chronic implantable artificial lung (P50 2045)

The single hardest engineering problem in this gate. Lungs require ~70 m² of gas-exchange surface area; no implantable artificial lung approaches that. Northwestern's 48-hour no-lungs case (Jan 2026) is the longest any human has survived without lungs — extracorporeal device only [6]. ECMO records are ~6 months bridge-to-transplant [13]. Pig lung xenotransplant (9-day record, Guangzhou Aug 2025) is the more plausible long-term path than synthetic [7]. P50 2045 assumes pig lung xeno reaches ~1-year survival and is the dominant lung replacement modality by then, with a 10-year safety record by ~2055.

### BCI speech restored in locked-in patient (P50 2031)

Already approaching threshold. ALS patient 62 wpm speech decoding via BCI (3x prior record); Neuralink VOICE trial (FDA Breakthrough Device Designation); Synchron COMMAND-12 patients with permanent endovascular implants and no serious adverse events over 12 months [19][20]. Communication for a brain-only patient is essentially a solved problem on a 5-8 year horizon. This sub-gate is far upstream of the main gate — its early arrival enables the "communicates and acts in the world" component of the trigger long before the multi-organ replacement is feasible.

### Head transplant / cephalic anastomosis in living human (P50 2065 if it happens at all)

This is the path the gate does NOT require. Even Canavero (the most aggressive advocate) has missed every public prediction since 2015. Spinal cord reconnection remains the binding scientific constraint. PEG/GEMINI fusogens show partial recovery in rodents and dogs but not at the cervical level. BrainBridge (May 2024) is a concept video, not a company. If cephalic anastomosis is required, this gate slides to 2080+. The more plausible path is progressive in-situ organ replacement that keeps spinal cord and vasculature continuous with the brain.

### Integrated multi-organ replacement platform (P50 2070)

The hardest unsolved problem. No medical center has attempted simultaneous TAH + artificial lung + artificial liver + dialysis + nutritional support in one patient. Each component has its own anticoagulation, infection, immune, and control-loop requirements that don't compose cleanly. Multi-organ ALLOTRANSPLANTATION (cadaveric heart+lung+liver+kidney, etc.) is performed in a few centers globally but failure rates are high and recipients are typically near death. The systems-integration problem is the binding constraint on this gate. P50 2070 reflects the multi-decade gap between single-organ replacement and integrated multi-organ platforms.

## Cross-gate interactions

**Human aging halted (P50 2048) <--> This gate: SUBSTITUTES, MEDIUM.** Both gates target life-extension but via opposite mechanisms (preserve-biology vs replace-biology). If aging is halted via geroprotectors and partial reprogramming, the consumer demand for body-replacement collapses to a small niche of patients whose body has failed catastrophically (severe burn, ALS late-stage, cancer cachexia) but whose brain is healthy. Conversely, if aging-halt fails or only partially works, body-replacement becomes the brute-force longevity option. The two gates are competing substitutes in the longevity stack. Aging-halt is converging faster (P50 22 years from now vs 49 years for this gate); body-replacement is likely the secondary, niche path.

**AI agent 30% knowledge work (P50 2029) --> This gate: ENABLES, MEDIUM.** AI accelerates drug discovery for novel immunosuppressants, CRISPR design for pig xenografts (eGenesis 69-gene-edit pigs are the AI-design ceiling today), organ-on-chip simulation, surgical planning, closed-loop artificial organ control, and BCI signal decoding. AI compresses biomedical R&D cycles 3-10x. The cross-effect pulls P10 forward by ~5 years but does not transform fundamental biological constraints (multi-organ integration, immunosuppression complexity).

**Humanoid self-replication factory (P50 2034) --> This gate: ENABLES, WEAK.** Humanoid manufacturing infrastructure could mass-produce artificial organ components and surgical robotic systems at lower cost; bioreactor automation reduces cost-per-organ-equivalent. Indirect path — humanoids don't directly build artificial hearts, but they reduce the unit cost of all complex medical hardware by 1-2 orders of magnitude. Effect is weak but directionally positive.

**Humanoid 10M households (P50 2035) <--> This gate: SUBSTITUTES, WEAK.** Humanoid eldercare in the home addresses some of the same fundamental demand (independence in advanced age or illness) at much lower cost and lower medical risk than body-replacement. Substitutive on the use-case dimension but only weakly — humanoid caregivers don't replace failing organs.

**Corporate sovereignty territory (P50 2070) <--> This gate: CORRELATES, WEAK.** Both gates require regulatory environments outside conventional national jurisdiction. Body-replacement is unlikely to be approved by FDA/EMA before 2050+ due to bioethics constraints; corporate medical zones or charter-city hospitals (Honduras, Próspera-type, Dubai medical free zones) may host the first procedures. Weak correlation through shared "jurisdiction-shopping" for cutting-edge medicine.

**Global economy explosive growth (P50 2049) <--> This gate: ENABLED_BY, MEDIUM.** Body-replacement at the integrated multi-organ scale is likely a $10-50M procedure even at maturity (each xenotransplant alone costs ~$1-2M with immunosuppression today). Without explosive growth in global wealth, the pool of patients who can afford it remains too small to sustain the clinical research infrastructure required to mature the technology. The two gates likely co-occur in the same wealth + tech wave.

## Sources

1. [World's First Genetically-Edited Pig Kidney Transplant into Living Recipient — Mass General](https://www.massgeneral.org/news/press-release/worlds-first-genetically-edited-pig-kidney-transplant-into-living-recipient)
2. [First person to receive genetically modified pig kidney transplant dies — NPR](https://www.npr.org/2024/05/12/1250835113/pig-kidney-transplant-richard-slayman)
3. [Man Lives 271 Days With Pig Kidney, Setting Medical Record — Infectious Disease Advisor](https://www.infectiousdiseaseadvisor.com/news/man-lives-271-days-with-pig-kidney-setting-medical-record/)
4. [Longest animal-to-human transplant — Nature Biotechnology](https://www.nature.com/articles/s41587-025-02912-5)
5. [First 'across the bridge': pig kidney recipient now has a human organ — CNN (Jan 2026)](https://us.cnn.com/2026/01/16/health/pig-kidney-human-organ-transplant)
6. [Artificial lung system keeps patient alive without lungs until transplant — Medical Xpress (Jan 2026)](https://medicalxpress.com/news/2026-01-artificial-lung-patient-alive-lungs.html)
7. [First pig lung transplanted into a person — Nature (Aug 2025)](https://www.nature.com/articles/d41586-025-02708-2)
8. [First 10-gene-edited pig-to-living-human auxiliary liver xenotransplantation — PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12764749/)
9. [Australian Man Survives 100 Days with BiVACOR Artificial Titanium Heart — MedPath](https://trial.medpath.com/news/92362c5b3d6b9a44/australian-man-survives-100-days-with-bivacor-artificial-titanium-heart-in-groundbreaking-trial)
10. [FDA grants BiVACOR Breakthrough designation for titanium TAH — MedTech Dive](https://www.medtechdive.com/news/bivacor-fda-breakthrough-titanium-total-artificial-heart/749506/)
11. [Total artificial heart faces defining chapter — American College of Surgeons (March 2026)](https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/bulletin/2026/march-2026-volume-111-issue-3/with-real-momentum-total-artificial-heart-technology-faces-defining-chapter/)
12. [United Therapeutics first transplant in EXPAND clinical trial of UKidney — IR (Nov 2025)](https://ir.unither.com/press-releases/2025/11-03-2025-120022270)
13. [Long-term ECMO 182 days bridge-to-transplant — PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11046094/)
14. [Wearable artificial kidneys — National Kidney Foundation](https://www.kidneyfund.org/news-stories/dream-starting-to-come-true-wearable-kidneys)
15. [Future of technology-based kidney replacement therapies — AJKD](https://www.ajkd.org/article/S0272-6386(25)00053-8/fulltext)
16. [Towana Looney longest-living pig kidney recipient — American Kidney Fund](https://www.kidneyfund.org/article/just-little-plain-country-girl-can-change-world-towana-looney-helps-break-new-ground-longest-living)
17. [Patient with transplanted pig kidney had rejection episode — STAT News](https://www.statnews.com/2024/04/08/xenotransplantation-pig-kidney-rejection-richard-slayman/)
18. [David Bennett pig heart transplant recipient dies — TCTMD](https://www.tctmd.com/news/david-bennett-first-transplant-recipient-pig-heart-dies)
19. [Neuralink Milestones 2025 — Cerebralink Neurotech](https://www.cerebralink.com/post/neuralink-s-milestones-in-2025-and-its-promising-future-in-2026)
20. [Synchron Command study positive results — MassDevice](https://www.massdevice.com/synchron-command-study-results-stentrode-bci-implant/)
21. [UC Irvine bidirectional BCI walking with sensation — UCI News (April 2026)](https://news.uci.edu/2026/04/16/uc-irvine-led-study-achieves-brain-controlled-walking-with-artificial-sensory-feedback/)
22. [Wandercraft Atalante X second FDA indication expansion — MassDevice (Nov 2025)](https://www.massdevice.com/fda-expands-indications-wandercraft-atalante-exoskeleton/)
23. [Robert White cephalic exchange transplantation in monkey — Wikipedia](https://en.wikipedia.org/wiki/Robert_J._White)
24. [Sergio Canavero biography and head transplant claims — Wikipedia](https://en.wikipedia.org/wiki/Sergio_Canavero)
25. [BrainBridge head transplant concept video — MIT Technology Review (May 2024)](https://www.technologyreview.com/2024/05/23/1092848/that-viral-video-showing-a-head-transplant-is-a-fake-but-it-might-be-real-someday/)
26. [Bexorg reactivated human brains CNS drug discovery — Longevity Technology](https://longevity.technology/news/transforming-cns-drug-discovery-using-reactivated-human-brains/)
27. [Cryopreservation brain cryonics and organ transplantation — MIT Technology Review (March 2026)](https://www.technologyreview.com/2026/03/24/1134562/cryopreservation-brain-cryonics-organ-transplantation/)
28. [Vertex Phase 1/2 zimislecel (VX-880) data 83% insulin-free — CGTLive](https://www.cgtlive.com/view/vertex-islet-cell-therapy-vx-880-restores-endogenous-insulin-secretion-type-1-diabetes)
29. [Restoration of brain circulation hours postmortem — PMC (BrainEx 2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6844189/)
30. [Yale BrainEx restores cell organ function — Yale News (2022)](https://news.yale.edu/2022/08/03/yale-developed-technology-restores-cell-organ-function-pigs-after-death)
31. [Theoretical possibilities of head transplant — arXiv](https://arxiv.org/pdf/2207.00304)
32. [Bridging the gap: spinal cord fusion (GEMINI/PEG) — PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6743693/)
33. [Whole brain transplantation in man: Technically feasible — Surgical Neurology International](https://surgicalneurologyint.com/surgicalint-articles/whole-brain-transplantation-in-man-technically-feasible/)
34. [Pig-to-human lung xenotransplantation review — PMC (2025)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12574424/)
35. [Cephalic exchange transplantation in the monkey — Surgery journal](https://www.surgjournal.com/article/0039-6060(71)90099-7/abstract)
36. [Brain organoid transplantation 233-day survival — PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC9556304/)
37. [Picard Medical IPO and Emperor TAH — SEC Form 8-K (2025)](https://www.sec.gov/Archives/edgar/data/0002030617/000182912625009304/picardmedical_ex99-1.htm)
38. [Neuralink VOICE Trial helps ALS patient speak — Basenor / NCT07256](https://www.basenor.com/blogs/news/neuralink-voice-trial-bci-helps-als-patient-speak-again)